These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 11881433)

  • 1. [Is the index of response to erythropoietin (IRE) a good marker of adequate dialysis?].
    Pérez-García R; Rodríguez-Benítez P; Villaverde MT; Valderrábano F
    Nefrologia; 2001; 21(6):606-7. PubMed ID: 11881433
    [No Abstract]   [Full Text] [Related]  

  • 2. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.
    Sobota JT
    Contrib Nephrol; 1989; 76():166-78; discussion 212-8. PubMed ID: 2684519
    [No Abstract]   [Full Text] [Related]  

  • 3. Human recombinant erythropoietin (rHuEPO) in the treatment of anemia in patients with chronic renal failure (CRF): experience with a group of patients on chronic haemodialysis treatment.
    Ramírez B; Flores A; Pérez F; Córdoba C; García L; Vázquez G
    Transplant Proc; 1991 Apr; 23(2):1833-4. PubMed ID: 2053170
    [No Abstract]   [Full Text] [Related]  

  • 4. Erythropoietin resistance and survival in non-dialysis patients with stage 4-5 chronic kidney disease and heart disease.
    Guerrero-Riscos MÁ; Montes-Delgado R; Seda-Guzmán M; Praena-Fernández JM
    Nefrologia; 2012 May; 32(3):343-52. PubMed ID: 22535158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of recombinant human erythropoietin on hematopoietic progenitors of chronic hemodialysis patients in vitro and in vivo.
    Hino M; Miyazono K; Urabe A; Takaku F
    Int J Cell Cloning; 1989 Jul; 7(4):257-63. PubMed ID: 2768843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of withdrawing erythropoietin.
    Taylor JE; Henderson IS; Mactier RA; Stewart WK
    BMJ; 1991 Feb; 302(6771):272-3. PubMed ID: 1998794
    [No Abstract]   [Full Text] [Related]  

  • 7. Secondary hyperparathyroidism as cause of resistance to treatment with erythropoietin: effect of parathyroidectomy.
    Goicoechea M; Gomez-Campdera F; Polo JR; Tejedor A; Ruiz MA; Vazquez I; Verde E; Valderrabano F
    Clin Nephrol; 1996 Jun; 45(6):420-1. PubMed ID: 8793241
    [No Abstract]   [Full Text] [Related]  

  • 8. Occult infection and resistance of anaemia to rHuEpo therapy in renal failure.
    Muirhead N; Hodsman AB
    Nephrol Dial Transplant; 1990; 5(3):232-4. PubMed ID: 2113653
    [No Abstract]   [Full Text] [Related]  

  • 9. [The importance of erythropoietin in the therapy of anemia in patients on chronic hemodialysis].
    von Appen K; Klinkmann H
    Urol Nefrol (Mosk); 1990; (6):69-70. PubMed ID: 2089771
    [No Abstract]   [Full Text] [Related]  

  • 10. Recombinant human erythropoietin (r-HuEPO): quality of life and other considerations.
    Tan A
    J CANNT; 1990; ():13-4. PubMed ID: 2202375
    [No Abstract]   [Full Text] [Related]  

  • 11. [A case of the good effect of low doses of erythropoietin].
    Shostka GD; Dobronravov VA; Vasil'ev AN
    Urol Nefrol (Mosk); 1991; (5):74-5. PubMed ID: 1755131
    [No Abstract]   [Full Text] [Related]  

  • 12. The anemia of chronic renal failure: pathophysiology and effects of recombinant erythropoietin.
    Eschbach JW; Haley NR; Adamson JW
    Contrib Nephrol; 1990; 78():24-36; discussion 37. PubMed ID: 2225841
    [No Abstract]   [Full Text] [Related]  

  • 13. Management of the chronic renal failure patient receiving epoetin alfa for the treatment of anemia.
    Binkley LS
    Transplant Proc; 1991 Apr; 23(2):1831-2. PubMed ID: 2053169
    [No Abstract]   [Full Text] [Related]  

  • 14. [Erythropoietin in renal anemia].
    Peña Amaro MP; García López J; Camacho Romera M
    Rev Enferm; 1992 Mar; 15(163):67-70. PubMed ID: 1565973
    [No Abstract]   [Full Text] [Related]  

  • 15. [Recombinant human erythropoietin and chronic kidney failure: current situation and therapeutic implications].
    Romero González R; Torquet Escuder P
    Med Clin (Barc); 1990 Nov; 95(17):656-9. PubMed ID: 2089205
    [No Abstract]   [Full Text] [Related]  

  • 16. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
    Besarab A; McCrea JB
    ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
    [No Abstract]   [Full Text] [Related]  

  • 17. Sub-optimal doses of human recombinant erythropoietin markedly lower serum ferritin.
    Jones-Lecointe A; Green PJ; Lee HA
    Clin Lab Haematol; 1991; 13(3):251-3. PubMed ID: 1794227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-related effects of recombinant human erythropoietin on erythropoiesis. Results of a multicenter trial in patients with end-stage renal disease.
    Bommer J; Kugel M; Schoeppe W; Brunkhorst R; Samtleben W; Bramsiepe P; Scigalla P
    Contrib Nephrol; 1988; 66():85-93. PubMed ID: 3292151
    [No Abstract]   [Full Text] [Related]  

  • 19. [Erythropoietin resistance].
    Branger B
    Nephrologie; 2002; 23(1):3-5. PubMed ID: 11887576
    [No Abstract]   [Full Text] [Related]  

  • 20. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
    Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.